China’s MOH Issues Notice On Strengthening Drug Use Surveillance
This article was originally published in PharmAsia News
China's Ministry of Health recently circulated a working draft on strengthening rational drug use surveillance nationwide. The scheme is jointly formulated by MOH, State Administration of Traditional Chinese Medicine and the health bureau under the General Logistics Department of the People's Liberation Army. MOH demands that all provincial-level health authorities instruct monitoring site hospitals in each council area to implement relevant work; these hospitals should ensure smooth progress in their surveillance. MOH will mainly be responsible for the surveillance work in grade three hospitals, while provincial health authorities will be in charge of rational drug use monitoring in grade two hospitals and basic-level health care institutions. (Click here for more - Chinese Language)
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.